Disrupting Healthcare: Median Technologies Secures $50 Million in Funding to Revolutionize Medical Imaging with AI

We are thrilled to announce that Median Technologies has successfully raised €50 million in a recent funding round, marking a significant milestone in our ongoing commitment to revolutionizing healthcare through innovative imaging solutions.

Established in 2002 and headquartered in the vibrant technology hub of Sophia-Antipolis, France, Median Technologies leverages advanced artificial intelligence to enhance the accuracy of cancer diagnosis and treatment, as well as to provide critical insights into novel therapies for patients facing metabolic diseases.

Our cutting-edge iCRO solutions facilitate precise medical image analysis and management in oncology trials, while our eyonis™ suite of AI/ML software-as-medical-devices empowers biopharmaceutical companies and clinicians to diagnose patients with unprecedented accuracy and speed.

The fresh capital will enable us to accelerate the development of our innovative technologies, expand our reach in global markets, and further enhance our capabilities in providing tailored solutions for healthcare professionals.

With a subsidiary in the US and another in Shanghai, we are strategically positioned to make a meaningful impact in the global healthcare landscape.

Recognized as an "Innovative company" by BPI and listed on the Euronext Growth market (ticker: ALMDT), we are also proud to be eligible for the French SME equity savings plan scheme (PEA-PME).

This funding underscores our commitment to creating a healthier world and reinforces our mission to ensure that transformative medical imaging technologies are accessible to all.